Benjamin F. Edwards & Company, Inc. Bluebird Bio, Inc. Transaction History

Benjamin F. Edwards & Company, Inc.

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.94 - $5.23 $429 - $763	-146 Closed	0 $0
Q1 2022 May 04, 2022	SELL	$4.07 - $10.6 $2,421 - $6,307	-595 Reduced 80.3%	146 $1,000
Q4 2021 Feb 07, 2022	BUY	$8.96 - $16.31 $188 - $342	21 Added 2.92%	741 $7,000
Q3 2021 Nov 02, 2021	SELL	$11.24 - $21.0 $7,069 - $13,209	-629 Reduced 46.63%	720 $14,000
Q2 2021 Aug 11, 2021	SELL	$18.04 - $22.09 $4,979 - $6,096	-276 Reduced 16.98%	1,349 $43,000
Q1 2021 May 14, 2021	SELL	$16.59 - $33.89 $1,244 - $2,541	-75 Reduced 4.41%	1,625 $49,000
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $37,015 - $51,040	-1,346 Reduced 44.19%	1,700 $74,000
Q3 2020 Nov 13, 2020	BUY	$34.44 - $43.75 $55,827 - $70,918	1,621 Added 113.75%	3,046 $164,000
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $15,594 - $26,432	575 Added 67.65%	1,425 $87,000
Q1 2020 May 07, 2020	BUY	$26.16 - $63.5 $4,342 - $10,541	166 Added 24.27%	850 $39,000
Q4 2019 Feb 06, 2020	SELL	$46.96 - $61.67 $563 - $740	-12 Reduced 1.72%	684 $60,000
Q3 2019 Nov 05, 2019	SELL	$59.47 - $93.1 $34,314 - $53,718	-577 Reduced 45.33%	696 $64,000
Q2 2019 Aug 08, 2019	BUY	$75.84 - $105.21 $96,544 - $133,932	1,273 New	1,273 $162,000
Q4 2018 Jan 31, 2019	SELL	$59.1 - $93.26 $5,378 - $8,486	-91 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$88.86 - $117.49 $888 - $1,174	10 Added 12.35%	91 $13,000
Q2 2018 Jul 19, 2018	BUY	$99.64 - $127.59 $2,690 - $3,444	27 Added 50.0%	81 $13,000
Q4 2017 Jan 17, 2018	BUY	$81.25 - $130.7 $812 - $1,307	10 Added 22.73%	54 $10,000
Q3 2017 Oct 24, 2017	BUY	$57.74 - $91.42 $2,540 - $4,022	44	44 $6,000

128

62.8M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $598M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.